FDA Determines Regulatory Review Period for EVENITY Patent Extension

Summary

The US Food and Drug Administration (FDA) has published a notice determining the regulatory review period for the patent extension of human biological product EVENITY, following a submission to the US Patent and Trademark Office (USPTO)